In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug July 8, 2021 Auto Bot Aduhelm (Drug), alzheimer's disease, Biogen Inc, Clinical Trials, Food and Drug Administration, Health Insurance and Managed Care, Labeling and Labels (Product) 0 The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.